Ancillary risk information and pharmacogenetic tests: Social and policy implications

Pharmacogenomics Journal

Volumn 8, Issue 2, 2008, Pages 85-89

  Henrikson, N B ^a   Burke, W ^a,b   Veenstra, D L ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ALCOHOLISM; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CONCEPTUAL FRAMEWORK; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATION; MENTAL DISEASE; MIGRAINE; NEURAL TUBE DEFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; STROKE;

BIOTRANSFORMATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC PRIVACY; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HUMANS; INCIDENTAL FINDINGS; MENTAL DISORDERS; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 40949153489     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500457     Document Type: Review

References (36)

1. Weinshilboum R. Inheritance and drug response. N Engl Med 2003; 348: 529-537.
2. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 1957; 165: 835-837.
3. Breckenridge A et al. Pharmacogenetics: Ethical problems and solutions. Nat Rev Genet 2004; 5: 676-680.
4. Buchanan A et al. Pharmacogenetics: Ethical issues and policy options. Kennedy Inst Ethics J 2002; 12: 1-15.
5. Sankar P, Kahn J. BiDil: Race Medicine Or Race Marketing? Health Aff (Millwood) 2005; Web exclusive: WS-W4$5, to W5-W463.
6. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003; 4: 937-947.
7. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18 344-360.
8. Lipton P, Afshar H, Bobrow CBE M, Caldwell J, Lindpaintner K, Rawlins M, Rose N, Starey N, Weale A. Pharmacogenetics: Ethical issues, (ed. Bioethics, N.C.o.) Nuffield Council on Bioethics, London, 2003.
9. Lehmann DJ et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005; 162: 305-317.
10. Rodriguez-Carreon AA et al. Tumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. J Autoimmun 2005; 24: 63-68.
11. Correa PA Gomez LM, Cadena J, Anaya JM. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism. J Rheumatol 2005; 32: 219-224.
12. Woolley N, Mustalahti K, Maki M, Partanen J. Cytokine gene polymorphisms and genetic association with coeliac disease in the Finnish population. Scand J Immunol 2005; 61: 51-56.
13. Yamamoto-Furusho JK et al. Polymorphisms in the promoter region of tumor necrosis factor alpha (TNF-alpha) and the HLA-DRB1 locus in Mexican mestizo patients with ulcerative colitis. Immunol Lett 2004; 95: 31-35.
14. Foley PF et al. Association studies of neurotransmitter gene polymorphisms in alcoholic Caucasians. Ann N Y Acad Sci 2004; 1025: 39-46.
15. Young RM, Lawford BR, Nutting A, Noble EP. Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 2004; 29: 1275-1294.
16. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: Effects of the DRD2 Taql RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 2004; 4: 102-109.
17. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers. Mol Psychiatry 2005; 10: 407-414.
18. Pritchard A et al. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett 2005; 382: 221-226.
19. Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr Opin Lipidol 2002; 13: 113-117.
20. Bailey LB. Folate, Methyl-Related Nutrients, Alcohol, and the MTHFR 677C → T Polymorphism Affect Cancer Risk: Intake Recommendations. J Nutr 2003; 133: 37485-33753.
21. Lea RA et al. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res Mol Brain Res 2005; 136: 112-117.
22. Relton CL et al. Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population. J Med Genet 2004; 41: 256-260.
23. Kelly PJ et al. Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurology 2002; 59: 529-536.
24. Hong YC et al. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer 2005; 116: 428-432.
25. La Torre G, Boccia S, Ricciardi G. Glutathione S-transferase M1 status and gastric cancer risk: A meta-analysis. Cancer Lett 2005; 217 53-60.
26. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Schwartz AG. GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: A population-based study. Carcinogenesis 2005; 26: 395-401.
27. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23: 1311-1325.
28. Boekholdt SM et al. Cholesteryl ester transfer protein TaqlB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: Individual patient meta-analysis of 13 677 subjects. Circulation 2005; 111: 278-287.
29. Davis BR et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J 2006.
30. Tantisira KG, Weiss ST. The pharmacogenetics of asthma: An update. Curr Opin Mol Ther 2005; 7: 209-217.
31. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005; 2: 475-483.
32. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38: 82-94.
33. Green MJ, Botkin JR. 'Genetic exceptionalism' in medicine: Clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003; 138: 571-575.
34. Gostin LO, Hodge JG. Genetic privacy and the law: An end to genetics exceptionalism. Jurimetrics 1999; 40: 21-58.
35. Faden RR et al. Public stem cell banks: Considerations of justice in stem cell research and therapy. Hastings Cent Rep 2003; 33 13-27.
36. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.